Shorter hormone treatment tested to fight prostate cancer with fewer side effects
NCT ID NCT06111781
Summary
This study is testing if adding a short course of an oral hormone-blocking drug (Relugolix) to a precise, high-dose radiation treatment (SBRT) works better than radiation alone for men with a specific type of intermediate-risk prostate cancer. The main goal is to see if the combination leads to lower PSA levels (a marker of cancer activity) while aiming to cause fewer long-term side effects like sexual dysfunction and fatigue compared to standard, longer hormone therapies. About 60 men will be randomly assigned to receive either the combination treatment or radiation alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10017, United States
Contact
Contact Email: •••••@•••••
-
University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.